AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35750681
Drug: IBI362 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI362 (3.0 mg, 4.5 mg or 6.0 mg)
Trial: 38508975
Drug: Topical clobetasol
RxNorm normalized name: clobetasol Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clobetasol
Trial: 35814305
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ESWT) with oral drug treatment
Trial: 35814305
Drug: Oral drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drug treatment only (Control)
Trial: 35038723
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg maintenance dose every 3 weeks
Trial: 35038723
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg maintenance dose every 3 weeks
Trial: 35038723
Drug: 2.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/kg maintenance dose every 3 weeks
Trial: 35038723
Drug: Induction dose
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dose alone
Trial: 35038723
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg maintenance dose
Trial: 35038723
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg maintenance dose
Trial: 35038723
Drug: 2.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g/kg maintenance dose
Trial: 34153943
Drug: Experimental therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapies with statistically significant OS endpoints (56 trials)
Trial: 34153943
Drug: Experimental therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapies with non-significant OS endpoints (131 trials)
Trial: 34153943
Drug: Experimental therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapies with PRS endpoints (total analyzed: 216)
Trial: 35362709
Drug: Modified surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified surgical approach (Method for surgical treatment of odontogenic oral phlegmon of mouth floor with partial dissection of sublingual‐submandibular sac)
Trial: 34667852
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BT) therapy
Trial: 33325799
Drug: RT234 (vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT234 (vardenafil inhalation powder) single doses of 0.2-2.4 mg
Trial: 33325799
Drug: RT234 (vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT234 (vardenafil inhalation powder) repeated doses of up to 2.4 mg q4h for four doses daily for 9 days
Trial: 33325799
Drug: RT234 (vardenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT234 (vardenafil inhalation powder)
Trial: 33325799
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vardenafil tablets (Levitra®)
Trial: 34187823
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (no treatment or any other treatment of their choice)
Trial: 32611865
Drug: Novel herbal
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel herbal anesthetic gel
Trial: 33783506
Drug: Intramuscular procaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular procaine G penicillin
Trial: 32926603
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) starting at 20 mg/d and titrated to a maximum of 70 mg/d
Trial: 33513650
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy containing anticoagulation, corticosteroids, and TPE or intravenous immunoglobulin in CAPS
Trial: 32513684
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect heterogeneity across baseline risk
Trial: 32513684
Drug: Economic models
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Economic models for RCT enrollment and treatment choice decisions
Trial: 33234644
Drug: Medicines at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicines at Transitions Intervention (MaTI)
Trial: 32876010
Drug: Isoniazid 900
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid 900 mg given twice weekly for 12 months
Trial: 34657346
Drug: Exergaming (interactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exergaming (interactive cycling at least twice a week for 6 months)
Trial: 33409540
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with steroids, six food elimination diet, mesalamine
Trial: 35679831
Drug: LAight® therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAight® therapy (8 sessions during period B)
Trial: 35679831
Drug: LAight® therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAight® therapy (group TC + L/L)
Trial: 35679831
Drug: LAight® therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAight® therapy (group TC/L)
Trial: 35679831
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% solution (group TC)
Trial: 35679831
Drug: Topical clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin 1% solution combined with LAight® therapy (group TC + L)
Trial: 35679831
Drug: LAight® therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAight® therapy (during period B)
Trial: 32852967
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with higher affiliative behaviors
Trial: 32852967
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with nonreciprocal relationship in dominance dimension
Trial: 32852967
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with complementarity in dominance dimension
Trial: 32852967
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy with interpersonal problems of communion
Trial: 616505213
Drug: Intraoperative injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of botulinum toxin A (BTA) in the orbicularis muscle below the lower punctum of both eyes (group B)
Trial: 616505213
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical treatment with preservative‐free tear substitutes only (group A)
Trial: 35972345
Drug: CIRAS model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRAS model based on ascites discomfort score, plasma sodium levels, and diuretic treatment.
Trial: 35972345
Drug: Standard ascites
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ascites classification (refractory vs. diuretic-responsive)
Trial: 36440779
Drug: Prospekta, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prospekta, 1 tablet twice daily
Trial: 34071714
Drug: n-3 PUFA-enriched
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA-enriched hen eggs (1053 mg/day)
Trial: 34743118
Drug: VYC-20L (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC-20L (20 mg/mL hyaluronic acid gel with lidocaine) administered via cannula
Trial: 34743118
Drug: Needle injection
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle injection of VYC-20L
Trial: 34743118
Drug: Injection-site responses
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection-site responses (ISRs)
Trial: 34864943
Drug: Investigator-assigned therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator-assigned therapy (IAT)
Trial: 616026142
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy, 3 sessions over 45 days
Trial: 34652564
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER intact capsule after a 10-h fast (control condition)
Trial: 34652564
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER intact capsule with a standard high-fat meal
Trial: 33507809
Drug: IMRT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT + C (60 Gy of intensity-modulated radiation therapy over 6 weeks with concurrent weekly cisplatin)
Trial: 33507809
Drug: IMRT (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT (60 Gy intensity-modulated radiation therapy over 5 weeks)
Trial: 32227643
Drug: Vilaprisan 2
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 2 mg (single oral dose)
Trial: 32942085
Drug: AMO-02 (tideglusib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMO-02 (tideglusib) 400 mg
Trial: 32942085
Drug: AMO-02 (tideglusib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMO-02 (tideglusib) 1000 mg
Trial: 32012977
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) over the left primary motor cortex for five days, combined with patient-controlled intravenous morphine analgesia (PCA-IV).
Trial: 32012977
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS stimulation, combined with patient-controlled intravenous morphine analgesia (PCA-IV).
Trial: 34129958
Drug: Stochastic finite
RxNorm normalized name: TITANIUM DIOXIDE 3.25 mL in 35 mL CUTANEOUS CREAM [PHYTOGENIC INFINITE FOUNDATION SPF20 NB21]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stochastic finite element model for bone-implant interface stiffness
Trial: 32336177
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with curcumin 0.75 mg/mL and blue LED (67 mW/cm2, 20.1 J/cm2)
Trial: 32918272
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 8–10 mg/kg of body weight
Trial: 32730930
Drug: ABGS (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABGS (250 μg rhBMP6/mL ABC)
Trial: 32567103
Drug: Telephone-guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-guided imagery rehearsal therapy
Trial: 33462450
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg kg‐1 every 2 weeks)
Trial: 32497217
Drug: Proximal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximal glucose infusion
Trial: 32497217
Drug: Distal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal glucose infusion
Trial: 34171822
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg b.i.d. for eight weeks
Trial: 32769647
Drug: Midurethral sling
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midurethral sling and behavioral and pelvic floor muscle therapy (combined group)
Trial: 34261911
Drug: Spleen aminopeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen aminopeptide oral lyophilized powder (SAOLP) 4 mg qd for two cycles
Trial: 34261911
Drug: Spleen aminopeptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen aminopeptide oral lyophilized powder (SAOLP)
Trial: 33507574
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg) administered 24 to 35 weeks after the last denosumab dose
Trial: 35899459
Drug: GOLDIC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOLDIC therapy
Trial: 35899459
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injections (dexamethasone)
Trial: 34479593
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (1g TXA IV)
Trial: 34479593
Drug: Peri-articular Injection
RxNorm normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri-articular Injection of Tranexamic Acid (1g TXA injected peri-articularly)
Trial: 33225963
Drug: Varenicline (promising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (promising AUD pharmacotherapy)
Trial: 36068705
Drug: IV sulopenem
RxNorm normalized name: Sulopenem
DrugBank: Sulopenem (DB15284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV sulopenem followed by oral sulopenem etzadroxil/probenecid
Trial: 36068705
Drug: IV ertapenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate
Trial: 33734910
Drug: Preservative-Free (PF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-Free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solution
Trial: 33734910
Drug: Preservative-Containing (PC)
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-Containing (PC) brimonidine/timolol fixed-combination (BTFC) ophthalmic solution
Trial: 33920626
Drug: Concurrent healthier
RxNorm normalized name: ALCOHOL 4 mL TOPICAL CLOTH [HEALTHIFY Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent healthier diet liking and healthier intake
Trial: 32720870
Drug: Bevacizumab (BEV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (BEV group; either monotherapy or with lomustine)
Trial: 32720870
Drug: Non-BEV group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-BEV group (lomustine monotherapy)
Trial: 32515412
Drug: Oral counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral counseling (OR) and the use of an application (App) for smartphones
Trial: 35317705
Drug: Progressive minimal
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive minimal changes to both first and second implants over a period of nine months to achieve balanced dynamic ranges.
Trial: 35317705
Drug: Changes to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes to their sequential implant only (Control group).
Trial: 34043719
Drug: Brazilian propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian propolis (5 tablets daily, 508.5 mg of propolis)
Trial: 34043719
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 tablets daily)
Trial: 35917763
Drug: ST+ABR (cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST+ABR (cognitive-behavioral therapy for smoking cessation and approach bias retraining)
Trial: 35917763
Drug: ST+Sham (cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST+Sham (cognitive-behavioral therapy for smoking cessation and sham retraining)
Trial: 33114210
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Superoxide Dismutase, Alpha Lipoic Acid, Acetyl L-Carnitine, and Vitamin B12 for 12 months
Trial: 32548864
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa hydrogel (twice daily for 60 days)
Trial: 32548864
Drug: Placebo hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hydrogel (twice daily for 60 days)
Trial: 35240263
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (WP) 20 g at breakfast + 20 g at dinner
Trial: 35240263
Drug: Placebo-maltodextrin (PL)
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-maltodextrin (PL) 20 g at breakfast + 20 g at dinner
Trial: 33258114
Drug: lanadelumab 300
RxNorm normalized name: lanadelumab 300 mg in 2 mL SUBCUTANEOUS SOLUTION [TAKHZYRO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lanadelumab 300 mg q2wks
Trial: 32167001
Drug: D-alanine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-alanine (60 mg/kg)
Trial: 35461158
Drug: Tofacitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (5 mg)
Trial: 35461158
Drug: Xeljanz® (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeljanz® (5 mg)
Trial: 32929234
Drug: ACC inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACC inhibitor (pharmacologic inhibition of acetyl‐CoA carboxylase)
Trial: 33070170
Drug: Horticultural Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural Therapy (HT) intervention over 6 months
Trial: 33445959
Drug: Interpersonal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal and Social Rhythm Therapy (IPSRT)
Trial: 33588758
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg once a day)
Trial: 34872511
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) treatment alone
Trial: 33038079
Drug: Comarum palustre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comarum palustre L. tablets 500 mg twice daily for 28 days
Trial: 33534226
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics only
Trial: 32887570
Drug: Sit-to-stand (STS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit-to-stand (STS) exercises combined with Oral Nutritional Supplements (ONS) intake
Trial: 36145090
Drug: Spirulina maxima
RxNorm normalized name: SPIRULINA MAXIMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina maxima 70% ethanol extract (SM70EE) 1 g/day
Trial: 33097279
Drug: Vaccinated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated with live LaSota ND vaccine (CV)
Trial: 33097279
Drug: Administered ND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered ND vaccine and 0.25 mg/kg body weight (BW) LPS (L‐LPS)
Trial: 33097279
Drug: Administered ND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered ND vaccine and 0.5 mg/kg BW LPS (H‐LPS)
Trial: 33394904
Drug: Low-frequency rTMS
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency rTMS with intensive speech therapy (ST)
Trial: 33394904
Drug: 2 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times a day low-frequency rTMS with intensive speech therapy (ST)
Trial: 33394904
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intensive speech therapy only)
Trial: 34618409
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection (ICI) of 100 units of BoNT‐A in 2 ml of saline
Trial: 34618409
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of saline (control)
Trial: 33044793
Drug: Lenvatinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (12 mg orally once daily for patients with a baseline body weight ≥60 kg and 8 mg orally once daily for patients with a baseline body weight <60 kg)
Trial: 34530868
Drug: mHealth, CPN‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth, CPN‐administered decision support intervention
Trial: 32447767
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution (JS)
Trial: 35436290
Drug: T13‐Jeevamrut 16.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T13‐Jeevamrut 16.08 L plant‐1 + Vermicompost 24.79 kg plant‐1
Trial: 34376536
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose glucocorticoids (GCC) use (≥60mg prednisone equivalent qd) after irAE onset
Trial: 34376536
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose GCC use